SEC Company Response from BIOLARGO, INC. (BLGO) (CIK 0000880242) (BLGO) — Jan 31, 2007
BIOLARGO, INC. (BLGO) (CIK 0000880242)
Date: Jan. 31, 2007 · CIK: 0000880242 · Accession: 0001144204-07-004581
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-19709
Letter
United States Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Re: NuWay Medical, Inc. Preliminary Proxy Statement on Schedule 14A Filed January 8, 2007 (SEC File No. 000-19709)
Dear Mr. Murao:
By letter of even date from our counsel SEC Law Firm, NuWay Medical Inc. (the “Registrant”) is responding to the written comments of the staff (the “Staff”) of the United States Securities and Exchange Commission (the “Commission”) dated January 26, 2007.
In connection with the foregoing response, the Registrant acknowledges that:
·
It is responsible for the adequacy and accuracy of the disclosure in its filings;
·
Staff comments of changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and
·
The Registrant may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very
truly yours,
/s/
Dennis Calvert
Show Raw Text
CORRESP
1
filename1.htm
NUWAY
MEDICAL, INC.
2603
Main Street, Suite 1155
Irvine,
CA 92614
Phone:
949-235-8062
January
31, 2007
Kurt
Murao, Esq.
United
States Securities and Exchange Commission
Division
of Corporation Finance
Washington,
D.C. 20549
Re:
NuWay Medical, Inc. Preliminary Proxy Statement on Schedule 14A Filed January
8,
2007 (SEC File No. 000-19709)
Dear
Mr.
Murao:
By
letter
of even date from our counsel SEC Law Firm, NuWay Medical Inc. (the
“Registrant”) is responding to the written comments of the staff (the “Staff”)
of the United States Securities and Exchange Commission (the “Commission”) dated
January 26, 2007.
In
connection with the foregoing response, the Registrant acknowledges
that:
·
It
is responsible for the adequacy and accuracy of the disclosure
in its
filings;
·
Staff
comments of changes to disclosure in response to Staff comments
do not
foreclose the Commission from taking any action with respect to
the
filing; and
·
The
Registrant may not assert Staff comments as a defense in any proceeding
initiated by the Commission or any person under the federal securities
laws of the United States.
Very
truly yours,
/s/
Dennis Calvert
Dennis
Calvert
President
and Chief Executive Officer